Lynparza approved in the EU for BRCA- mutated metastatic pancreatic cancer
8 July 2020 07:00 BST Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer Only PARP inhibitor approved in this disease AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that Lynparza (olaparib) has been approved in the European Union (EU) for patients with germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer. Pancreatic cancer is a rare, life-threatening disease with the lowest survival rate among the most common cancers.[1] Approximately 5-7% of patients with metastatic